Literature DB >> 27689339

Circulating immune cells in multiple sclerosis.

A P Jones1, A G Kermode2,3, R M Lucas4, W M Carroll2,3, D Nolan3,5, P H Hart1.   

Abstract

Circulating T and B lymphocytes contribute to the pathogenesis of the neuroinflammatory autoimmune disease, multiple sclerosis (MS). Further progress in the development of MS treatments is dependent upon a greater understanding of the immunological disturbances that underlie the disease. Analyses of circulating immune cells by flow cytometry have revealed MS-associated alterations in the composition and function of T and B cell subsets, including temporal changes associated with disease activity. Disturbances in circulating immune populations reflect those observed in the central nervous system and include skewing towards proinflammatory CD4+ and CD8+ T cells and B cells, greater proportions of follicular T helper cells and functional defects in the corresponding T and B regulatory subsets. Utilizing the analytical power of modern flow cytometers, researchers are now well positioned to monitor immunological changes associated with disease activity or intervention, describe immunological signatures with predictive value and identify targets for therapeutic drug development. This review discusses the contribution of various T and B lymphocyte subsets to MS pathogenesis, provides current and relevant phenotypical descriptions to assist in experimental design and highlights areas of future research.
© 2016 British Society for Immunology.

Entities:  

Keywords:  B cells; T cells; flow cytometry; multiple sclerosis

Mesh:

Year:  2016        PMID: 27689339      PMCID: PMC5217886          DOI: 10.1111/cei.12878

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  98 in total

Review 1.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  J M Fletcher; S J Lalor; C M Sweeney; N Tubridy; K H G Mills
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

2.  IL-11 Induces Th17 Cell Responses in Patients with Early Relapsing-Remitting Multiple Sclerosis.

Authors:  Xin Zhang; Yazhong Tao; Manisha Chopra; Irena Dujmovic-Basuroski; Jianping Jin; Yunan Tang; Jelena Drulovic; Silva Markovic-Plese
Journal:  J Immunol       Date:  2015-04-20       Impact factor: 5.422

3.  Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells.

Authors:  Aharon Kessel; Tharwat Haj; Regina Peri; Ayelet Snir; Doron Melamed; Edmond Sabo; Elias Toubi
Journal:  Autoimmun Rev       Date:  2011-12-02       Impact factor: 9.754

4.  CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation.

Authors:  Fabian Flores-Borja; Anneleen Bosma; Dorothy Ng; Venkat Reddy; Michael R Ehrenstein; David A Isenberg; Claudia Mauri
Journal:  Sci Transl Med       Date:  2013-02-20       Impact factor: 17.956

5.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Authors:  Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri
Journal:  Immunity       Date:  2010-01-14       Impact factor: 31.745

6.  IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells.

Authors:  Rebecca Noster; René Riedel; Mir-Farzin Mashreghi; Helena Radbruch; Lutz Harms; Claudia Haftmann; Hyun-Dong Chang; Andreas Radbruch; Christina E Zielinski
Journal:  Sci Transl Med       Date:  2014-06-18       Impact factor: 17.956

Review 7.  IL-10-producing regulatory B cells (B10 cells) in autoimmune disease.

Authors:  Ioannis Kalampokis; Ayumi Yoshizaki; Thomas F Tedder
Journal:  Arthritis Res Ther       Date:  2013-02-11       Impact factor: 5.156

Review 8.  Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis.

Authors:  Rui Li; Ayman Rezk; Luke M Healy; Gillian Muirhead; Alexandre Prat; Jennifer L Gommerman; Amit Bar-Or
Journal:  Front Immunol       Date:  2016-01-08       Impact factor: 7.561

Review 9.  Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications.

Authors:  Giordani Rodrigues Dos Passos; Douglas Kazutoshi Sato; Jefferson Becker; Kazuo Fujihara
Journal:  Mediators Inflamm       Date:  2016-01-28       Impact factor: 4.711

10.  Increased expression of Tbet in CD4(+) T cells from clinically isolated syndrome patients at high risk of conversion to clinically definite MS.

Authors:  Christopher McGuigan; Jean M Fletcher; Sharee A Basdeo; Siobhan Kelly; Karen O'Connell; Niall Tubridy
Journal:  Springerplus       Date:  2016-06-18
View more
  28 in total

1.  1,25-dihydroxyvitamin D3 -induced dendritic cells suppress experimental autoimmune encephalomyelitis by increasing proportions of the regulatory lymphocytes and reducing T helper type 1 and type 17 cells.

Authors:  Zhongxiang Xie; Jingtao Chen; Chao Zheng; Jing Wu; Yun Cheng; Shan Zhu; Chenhong Lin; Qingqing Cao; Jie Zhu; Tao Jin
Journal:  Immunology       Date:  2017-07-10       Impact factor: 7.397

Review 2.  The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings.

Authors:  Helen Tremlett; Emmanuelle Waubant
Journal:  Neurotherapeutics       Date:  2018-01       Impact factor: 7.620

3.  Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.

Authors:  Erin E Longbrake; Claudia Cantoni; Salim Chahin; Francesca Cignarella; Anne H Cross; Laura Piccio
Journal:  Mult Scler       Date:  2017-05-08       Impact factor: 6.312

4.  Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation.

Authors:  F G Karnell; D Lin; S Motley; T Duhen; N Lim; D J Campbell; L A Turka; H T Maecker; K M Harris
Journal:  Clin Exp Immunol       Date:  2017-06-07       Impact factor: 4.330

5.  Unsupervised capture and profiling of rare immune cells using multi-directional magnetic ratcheting.

Authors:  Coleman Murray; Hiromi Miwa; Manjima Dhar; Da Eun Park; Edward Pao; Jessica Martinez; Sireesha Kaanumale; Evelina Loghin; John Graf; Khadir Raddassi; William W Kwok; David Hafler; Chris Puleo; Dino Di Carlo
Journal:  Lab Chip       Date:  2018-08-07       Impact factor: 6.799

6.  Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.

Authors:  M C González-Oria; M Márquez-Coello; J A Girón-Ortega; J Argente; M Moya; José-Antonio Girón-González
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-16       Impact factor: 4.147

7.  Expression analysis of long non-coding RNAs and their target genes in multiple sclerosis patients.

Authors:  Maziar Ganji; Arezou Sayad; Mir Davood Omrani; Shahram Arsang-Jang; Mehrdokht Mazdeh; Mohammad Taheri
Journal:  Neurol Sci       Date:  2019-01-24       Impact factor: 3.307

8.  Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy.

Authors:  Francesca Rinaldi; Lisa Federle; Marco Puthenparampil; Paola Perini; Francesca Grassivaro; Paolo Gallo
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-12-13

9.  Teriflunomide treatment reduces B cells in patients with MS.

Authors:  Ilaria Gandoglia; Federico Ivaldi; Alice Laroni; Federica Benvenuto; Claudio Solaro; Gianluigi Mancardi; Nicole Kerlero de Rosbo; Antonio Uccelli
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-10-23

10.  Toll-Like Receptor Homolog CD180 Expression Is Diminished on Natural Autoantibody-Producing B Cells of Patients with Autoimmune CNS Disorders.

Authors:  Zsófia Hayden; Szabina Erdő-Bonyár; Beáta Bóné; Noémi Balázs; Kornélia Bodó; Zsolt Illes; Timea Berki; Diána Simon
Journal:  J Immunol Res       Date:  2021-05-25       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.